Navigation Links
Key leukemia defense mechanism discovered by VCU Massey Cancer Center
Date:9/30/2010

Richmond, Va. (September 30, 2010) Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., and a team of VCU Massey researchers have uncovered the mechanism by which leukemia cells trigger a protective response when exposed to a class of cancer-killing agents known as histone deacetylase inhibitors (HDACIs). The findings, published in the Journal of Biological Chemistry, could lead to more effective treatments in patients with leukemia and other cancers of the blood.

"Our findings provide new insights into the ways such cancer cells develop resistance to and survive treatment," says Grant, associate director for translational research and professor of medicine. "This knowledge will now allow us to focus our efforts on strategies designed to prevent these self-protective responses, potentially rendering the cancer cell incapable of defense and increasing the effectiveness of therapy."

The discovery centers on modification of a protein known as NEMO. Researchers have known for some time that HDACIs trigger a protective response in leukemia cells by activating a survival signaling pathway known as NF-κB, which limits the ability of HDACIs to initiate a cancer cell suicide program known as apoptosis. However, it was previously thought this process occurred through activation of receptors residing on the cancer cell surface. What VCU Massey researchers discovered was that HDACIs initially induce DNA damage within the cell nucleus, leading to modification of the NEMO protein, which then triggers the cytoprotective NF-κB pathway. By disrupting modifications of the NEMO protein, NF-κB activation can be prevented, and as a consequence, the cancer-killing capacity of HDACIs increases dramatically.

HDACIs represent an approved form of treatment for certain forms of lymphoma, and VCU Massey Cancer Center has been working for over seven years to develop strategies designed to improve their effectiveness in leukemia and other blood cancers. Grant's team is now focusing on ways to capitalize on this discovery by designing strategies that interrupt NEMO modifications through the use of pharmacologic agents and other means.

"Our goal is to move these findings from the laboratory to the bedside as quickly as we possibly can. There are currently several drugs in early stages of development that hold promise in disrupting the NEMO-related NF-κB pathway, but further research defining their safety and effectiveness will be required before we can incorporate them into new therapies," says Grant.


'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Researcher at Childrens Hospital LA discovers way to overcome radiation resistance in leukemia
2. Experimental Leukemia Drug Proves a Slam Dunk
3. New driver of T cell leukemia growth
4. Targeted agent shows promise for chronic lymphoid leukemia
5. Technique to preserve fertility in young women may be unsafe for patients with leukemia
6. UCSF-led team discovers familial link in rare childhood leukemia
7. Research consortium at CHLA receives $410,000 to study leukemia and lymphoma
8. Stem cell transplantation of therapy-resistant chronic leukemia successful
9. Combination therapy targets stubborn leukemia stem cells
10. Gene loss causes leukemia
11. Genetic Pattern May Predict Leukemia Relapse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... Amir Qureshi, MD is the first physician in Arkansas ... stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a treatment ... in Arkansas to introduce the most powerful SCS system and the only stretchable lead ...
(Date:5/26/2017)... MA (PRWEB) , ... May 26, 2017 , ... On ... Act (AHCA), which narrowly passed the U.S. House on May 4, would result in ... be expected under continued implementation of the 2010 Patient Protection and Affordable Care Act ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled ... a new, informational blog post on insurance options. If a Bay Area patient has ... help save time and money. Visiting an in-network provider for a second opinion can ...
(Date:5/26/2017)... ... 2017 , ... “Cactus Jack: Against All Odds”: the story of Coach Cactus ... Against All Odds” is the creation of published author, Walter Hubbard, a retired wildlife ... Carlisle’s third child Jane. Walter. Walter and Jane have three adult children and ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Altec ... participation in nVerge 2017 – a one-day technology conference in San Diego, CA. ... solution, which allows users to fully utilize and enhance their Sage ERP solutions by ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... -- Global Health Intelligence (GHI), the leading healthcare ... published its 2017 ranking of the Best-Equipped Hospitals in ... analysis from GHI,s hospitals database for Latin America , ... The GHI database covers 86% of the hospitals in ... points for each institution in key areas such as beds, ...
(Date:5/9/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... it has earned a spot on Forbes, ... was ranked among 500 U.S. employers as well as ... and Services. The annual Forbes ... survey of over 30,000 employees across 25 industries. The ...
(Date:5/8/2017)... NEW YORK , May 8, 2017 ... in the transition from fee for service reimbursement. Black ... April 2017. 1.       The Market for ... 77% of physician practices with 3 or ... Compliance Technology Solutions by Q4. "Given the magnitude of ...
Breaking Medicine Technology: